AOTI Inc (AIM:AOTI) CEO, president, and co-founder Dr Mike Griffiths talked with Proactive about the company’s efforts to revolutionise chronic wound care. AOTI is focused on treating conditions like diabetic foot ulcers with its unique home-based oxygen therapy, designed to promote durable healing.
Griffiths highlighted the staggering $80 billion US diabetic foot ulcer care market and shared that AOTI is well-positioned to expand within this space. He noted that AOTI’s strong clinical evidence and ability to reduce hospitalisations and amputations resonate strongly with payers and healthcare providers.
He also shared recent milestones, including the company’s expansion into six Medicaid states, its five-year renewal of the Veterans Affairs contract, and ongoing efforts to broaden its international presence. Griffiths announced the start of enrolments for the venous leg ulcer (VLU) clinical trial and discussed its significance in building high-quality evidence for AOTI's therapy.
AOTI, headquartered in the US and listed on AIM, has grown by over 30% annually for five years and Griffiths expects this growth to continue as it enters new markets like skilled nursing and long-term care. “We believe we’re in a very exciting sector, with solutions that deliver long-term outcomes,” he shared.